MEHC.Q Stock Overview
Operates as a consumer genetics testing company in the United States, the United Kingdom, Canada, and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
Community vs My Fair Value
Create NarrativeSelect a narrative for quick price alerts from the community, or create your own.
23andMe Holding Co. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$1.04 |
| 52 Week High | US$12.76 |
| 52 Week Low | US$0.48 |
| Beta | 1.52 |
| 1 Month Change | -24.09% |
| 3 Month Change | -72.56% |
| 1 Year Change | -88.96% |
| 3 Year Change | -98.48% |
| 5 Year Change | n/a |
| Change since IPO | -99.47% |
Recent News & Updates
Recent updates
Here's Why We're A Bit Worried About 23andMe Holding's (NASDAQ:ME) Cash Burn Situation
Apr 16
Risks Still Elevated At These Prices As 23andMe Holding Co. (NASDAQ:ME) Shares Dive 26%
Mar 02We're Keeping An Eye On 23andMe Holding's (NASDAQ:ME) Cash Burn Rate
Jul 1323andMe Holding Co. (NASDAQ:ME) Investors Are Less Pessimistic Than Expected
Jun 15Shareholder Returns
| MEHC.Q | US Healthcare | US Market | |
|---|---|---|---|
| 7D | 35.1% | 2.9% | -5.6% |
| 1Y | -89.0% | 5.4% | 3.3% |
Return vs Industry: MEHC.Q underperformed the US Healthcare industry which returned 2.2% over the past year.
Return vs Market: MEHC.Q underperformed the US Market which returned 8.4% over the past year.
Price Volatility
| MEHC.Q volatility | |
|---|---|
| MEHC.Q Average Weekly Movement | 32.0% |
| Healthcare Industry Average Movement | 6.9% |
| Market Average Movement | 6.8% |
| 10% most volatile stocks in US Market | 16.8% |
| 10% least volatile stocks in US Market | 3.4% |
Stable Share Price: MEHC.Q's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: MEHC.Q's weekly volatility has increased from 20% to 32% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2006 | 571 | Joe Selsavage | www.23andme.com |
23andMe Holding Co. operates as a consumer genetics testing company in the United States, the United Kingdom, Canada, and internationally. The company operates in two segments, Consumer and Research Services, and Therapeutics. The Consumer and Research Services segment provides personal genome service (PGS) that consists of a suite of genetic reports, including information on customers’ genetic ancestral origins, personal genetic health risks, and chances of passing on certain rare carrier conditions to their children, as well as reports on how genetics can impact responses to medications.
23andMe Holding Co. Fundamentals Summary
| MEHC.Q fundamental statistics | |
|---|---|
| Market cap | US$33.27m |
| Earnings (TTM) | -US$426.19m |
| Revenue (TTM) | US$208.78m |
0.1x
P/S Ratio-0.1x
P/E RatioIs MEHC.Q overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| MEHC.Q income statement (TTM) | |
|---|---|
| Revenue | US$208.78m |
| Cost of Revenue | US$98.06m |
| Gross Profit | US$110.72m |
| Other Expenses | US$536.91m |
| Earnings | -US$426.19m |
Last Reported Earnings
Dec 31, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -15.89 |
| Gross Margin | 53.03% |
| Net Profit Margin | -204.14% |
| Debt/Equity Ratio | 0% |
How did MEHC.Q perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/04/03 05:27 |
| End of Day Share Price | 2025/04/03 00:00 |
| Earnings | 2024/12/31 |
| Annual Earnings | 2024/03/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
23andMe Holding Co. is covered by 3 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Gaurav Goparaju | Berenberg |
| Daniel Grosslight | Citigroup Inc |
| Parth Talsania | Equisights |